Braveheart Bio raised $382.5M in its IPO, pricing shares at $18. The San Francisco biotech is developing a drug for ...
More than 40 class-action lawsuits were filed against 23andMe as a result of the hacking. Those cases were centralized in U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results